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The nucleotide-binding domain and leucine-rich-
repeat-containing (NLR) proteins regulate innate
immunity. Although the positive regulatory impact
of NLRs is clear, their inhibitory roles are not well
defined. We showed that Nlrx1/ mice exhibited
increased expression of antiviral signaling molecules
IFN-b, STAT2, OAS1, and IL-6 after influenza virus
infection. Consistent with increased inflammation,
Nlrx1/mice exhibited marked morbidity and histo-
pathology. Infection of these mice with an influenza
strain that carries a mutated NS-1 protein, which
normally prevents IFN induction by interaction
with RNA and the intracellular RNA sensor RIG-I,
further exacerbated IL-6 and type I IFN signaling.
NLRX1 also weakened cytokine responses to the
2009 H1N1 pandemic influenza virus in human
cells. Mechanistically, Nlrx1 deletion led to constitu-
tive interaction of MAVS and RIG-I. Additionally, an
inhibitory function is identified for NLRX1 during
LPS activation of macrophages where the MAVS-
RIG-I pathway was not involved. NLRX1 interacts
with TRAF6 and inhibits NF-kB activation. Thus,
NLRX1 functions as a checkpoint of overzealous
inflammation.
INTRODUCTION
A hallmark of the innate immune response to influenza virus infec-
tion is the induction of antiviral cytokines and inflammation.
However, an overzealous immune response is deleterious to the
host when left unchecked. Host viral recognition is facilitated by
three families of pattern recognition receptors (PRRs) that sense854 Immunity 34, 854–865, June 24, 2011 ª2011 Elsevier Inc.pathogen-associated molecular patterns (PAMPs): the RIG-I like
helicase (RLH) family, the Toll-like receptor (TLR) family, and
the nucleotide binding domain (NBD) and leucine-rich-repeat-
containing (NLR) family.Members of theNLR family are indispens-
able for both in vivo and cellular responses topathogens, including
the influenza A virus (Allen et al., 2009; Thomas et al., 2009).
Previous in vitro studies have shown that NLRX1 (a member of
NLR) functions as an attenuator of RLH-mediated interferon-
b (IFN-b) signaling (Moore et al., 2008). NLRX1was found localized
in the mitochondrial outer membrane and interacts with the mito-
chondrial antiviral signaling (MAVS) protein to disrupt virus-
induced RLH-MAVS interactions (Moore et al., 2008).
After influenza virus infection, single-stranded viral RNA is
detected by RIG-I (Le Goffic et al., 2007; Rehwinkel et al.,
2010), which then interacts with MAVS, leading to ubiquitin
ligases TRAF3- and TRAF6-dependent transcription of type I
IFN (IFN-I)- and NF-kB-responsive genes, respectively (Kawai
et al., 2005; Seth et al., 2005). Influenza employs its nonstructural
protein 1 (NS1) to subvert the RIG-I pathway (Guo et al., 2007;
Pichlmair et al., 2006). The mammalian genome also encodes
several negative regulators of MAVS signaling, although the
in vivo relevance of most of these molecules has not been vali-
dated (Jia et al., 2009; Jounai et al., 2007; Moore et al., 2008;
Xu et al., 2009; Yasukawa et al., 2009; You et al., 2009).
NLRX1 represents an NLR that functions as a modulator of
PAMP receptors, rather than an actual receptor or sensor.
Here we showed that NLRX1 is a negative in vivo regulator of
the innate immune response to viral infection. We generated
aNlrx1/mouse strain and demonstrated that NLRX1 functions
to downregulate specific components of the IFN-I response and
IL-6 signaling during influenza virus infection. Furthermore, we
extend the relevancy of these findings by establishing that
NLRX1 downregulates several interferon response genes and
IL-6 in human cells infected with the 2009 pandemic influenza
A virus. Mechanistically, our data show that NLRX1 functions
as an attenuator of inflammation by intersecting the MAVS and
TRAF6 pathways.
Immunity
NLRX1 Is a Negative Regulator of Viral ImmunityRESULTS
NLRX1 Functions as a Negative Regulator
of IFN-b Production
To study the role of NLRX1 in vivo, we generated amutantmouse
by disrupting the nucleotide binding domain (NBD) with a
neomycin cassette (Figures 1A and 1B; see Figures S1A–S1C
available online). Fibroblasts isolated from Nlrx1/ mice were
completely devoid of NLRX1 protein (Figure 1C). Our earlier
in vitro analysis in cell lines concluded that NLRX1 functions as
an attenuator of viral-induced MAVS-mediated IFN-I production
(Moore et al., 2008). Therefore, we assessed Ifnb1 expression in
Nlrx1/ mouse fibroblasts. Constitutive Ifnb1 expression was
equivalent between unstimulated wild-type (WT) and Nlrx1/
fibroblasts (Figure S1D), indicating that NLRX1 does not affect
basal IFN expression. However, transfection of the synthetic
RNA analog poly(I:C) into cells caused significantly more Ifnb1
transcript and IFN-b protein in Nlrx1/ fibroblasts relative to
WT controls (Figure 1D). These data suggest that NLRX1 func-
tions as an attenuator of IFN-b production in response to dsRNA,
which is an RLH agonist.
Earlier reports found elevated reactive oxygen species (ROS)
subsequent to overexpression of NLRX1 (Abdul-Sater et al.,
2010; Tattoli et al., 2008). To assess this in a physiologically
relevant model, we measured ROS in stimulated neutrophils
and macrophages isolated from WT and Nlrx1/ mice. We
observed a small, quarter log reduction in basal ROS produced
from Nlrx1/ neutrophils and macrophages and in neutrophils
stimulated with Pam3Cys (Figure 1E; Figures S1E and S1F).
However, ROS amounts were not markedly altered after
PAMP stimulation with any other agonist in either cell type
(Figures S1E and S1F). Thus, NLRX1 probably plays a minimal
role in ROS production.
NLRX1 Inhibits the Interaction between MAVS and RIG-I
and Functions as a Negative Regulator of Virus Infection
Previous studies with fibroblasts isolated from eitherMavs/ or
Ddx58/ (RIG-I-deficient) mice revealed that loss of either
protein resulted in significantly reduced amounts of IFN-b in
response to Sendai virus and vesicular stomatitis virus (Kato
et al., 2005; Sun et al., 2006). To assess the role of NLRX1, we
challenged primary fibroblasts from our Nlrx1/ mice with a
panel of viruses designed to evaluate RIG-I and MDA5 signaling.
These viruses included simian virus 5 (SV5), encephalomyocar-
ditis virus (EMCV), Sendai virus (SeV), vesicular stomatitis virus
(VSV), and influenza A virus (A/PR/8/34). We observed a signifi-
cant increase in IFN-b production in Nlrx1/ fibroblasts after
challenges with SV5, SeV, VSV, and influenza A virus (Figures
1F–1H). However, the amount of IFN-b induced by ECMV was
unaffected by NLRX1 deficiency (Figure 1G). Because a previous
study showed that VSV-induced IFN-b production in MEFs was
RIG-I dependent, whereas EMCV-induced IFN-b production
was MDA5 specific (Kato et al., 2006), these data suggest that
NLRX1 negatively regulates MAVS signaling that relies on
RIG-I-, but not MDA-5-, dependent recognition of viruses.
To observe the kinetics of IFN-b production in the context of
NLRX1 deficiency, we assayed SeV-infected samples over a
time course. We utilized SeV because it is a well-characterized
virus and a known activator of RIG-I. After SeV infection, Ifnb1expression was markedly increased in the Nlrx1/ fibroblasts
between 3 and 24 hr after infection (Figure 1I). IFN-b protein
amounts lagged behind transcription and were markedly
enhanced at 24 hr after infection in Nlrx1/ fibroblasts (Fig-
ure 1J). In addition to IFN-b, previous studies have also shown
that IL-6 production in MEFs after SeV infection is dependent
upon MAVS signaling (Sun et al., 2006). Therefore, we expanded
our analysis by assessing IL-6 production in Nlrx1/MEFs after
virus challenge. Nlrx1/MEFs produced significantly increased
amounts of IL-6 in response to SV5, SeV, VSV, and influenza
virus infection (Figures 1K and 1L). To complement the virus
studies and to further confirm the inhibitory nature of NLRX1,
primary MEFs from Nlrx1/ mice were stably transfected with
a construct encoding full-length human NLRX1. After transfec-
tion with poly(I:C), reconstituted MEFs were capable of attenu-
ating Ifnb1 and Il6 gene transcription (Figure 1M). Together,
these data suggest that NLRX1 functions as a negative regulator
of both IFN-I signaling and IL-6 production in primary MEFs after
challenges with RIG-I-inducing viruses.
Previous data suggested that the introduction of exogenous
NLRX1 can inhibit the association of RIG-I with MAVS (Moore
et al., 2008). To test this ex vivo, we examined the association
of endogenous RIG-I or MDA-5 with MAVS after SeV and
EMCV infections in fibroblasts that were isolated from WT and
Nlrx1/ mice. The RIG-I-MAVS association occurred constitu-
tively in Nlrx1/ cells in the absence of viral infection, whereas
this association was not seen until 6 hr after infection inWT fibro-
blasts (Figures 1N and 1O). The MDA5-MAVS interaction
required stimulation by EMCV and was increased 24 hr after
infection in the absence of NLRX1 (Figure 1N). The enhanced
association between RIG-I and MAVS could, at least partially,
explain the robust nature of the virus-induced IFN-b secretion
in Nlrx1/ fibroblasts.
NLRX1 Is an Attenuator of LPS-Induced IFN-b
and IL-6 Production in Macrophages
The essential role of MAVS in RIG-I-mediated antiviral innate
immunity is cell type specific (Kato et al., 2005; Sun et al.,
2006). To address potential cell type differences in NLRX1 func-
tion, we assessed the role of NLRX1 in myeloid-derived cells
after poly(I:C) stimulation. There were no differences in Ifnb1
expression or IFN-b production from Nlrx1/ and WT bone
marrow-derived macrophages stimulated with either poly(I:C)
(MAVS) or 30-ppp-RNA (RIG-I) (Figures 2A and 2B). We also
generated plasmacytoid dendritic cells (pDCs), which are robust
producers of IFN. There were no differences in IFN-b production
from Nlrx1/ pDCs stimulated with the known TLR7 agonist
R848, TLR9 agonist CpG, or TLR3 agonist poly(I:C) (Figure S1G).
To determine whether NLRX1 also contributes to bacteria-
induced IFN-b production, we challenged macrophages with
either Legionella pneumophila or Listeria monocytogenes. Both
of these bacteria are known to induce high amounts of IFN-b in
macrophages. However, after in vitro infection, we did not
observe a difference in Ifnb1 expression between WT and
Nlrx1/ macrophages (Figure S1H). This indicates that NLRX1
does not play an obvious role in IFN-b induction by these
bacteria.
In macrophages, the production of IFN-b and IL-6 after LPS
stimulation occurs through a MAVS-independent mechanismImmunity 34, 854–865, June 24, 2011 ª2011 Elsevier Inc. 855
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Figure 1. NLRX1 Functions as a Negative Regulator of IFN-I Production
(A) Schematic of the generation of Nlrx1/ mice through homologous recombination.
(B) PCR genotyping of offspring from heterozygous matings.
(C) Confirmation of the loss of NLRX1 protein in Nlrx1/ offspring by immunoblot.
(D) Ifnb1 transcript and IFN-b protein were assessed in MEFs that were transfected with poly(I:C).
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Immunity
NLRX1 Is a Negative Regulator of Viral Immunity(Sun et al., 2006). The data shown in Figure 1 suggest that RIG-I
and MAVS are constitutively associated in Nlrx1/ MEFs,
which probably contributes to the increased amounts of IL-6
that we observed after virus stimulation in this cell type. Unlike
the MEF data, a role for Nlrx1 in attenuating IL-6 was not
observed in macrophages stimulated with transfected poly(I:C),
which is consistent with the literature (Figure 2C). In addition to
poly(I:C), we also examined the induction of IFN-b and IL-6 in
macrophages stimulated by LPS. Under these conditions,
Nlrx1/ macrophages produced significantly more IFN-b and
IL-6 after LPS stimulation (Figures 2D and 2E). We also as-
sessed the production of IL-1b and observed a significant
increase in IL-1b production in the Nlrx1/ macrophages (Fig-
ure 2F). This suggests that the function of NLRX1 is not specific
to IL-6. In addition to LPS, we did not observe a significant
difference between WT and Nlrx1/ macrophages stimulated
with either TNF-a or Pam3CSK4 (Figures S1I and S1J). LPS is
an agonist for the TLR4 receptor, where signal transduction is
facilitated through MyD88, TRAF3, and TRAF6 to mediate
IFN-I production and canonical NF-kB-initiated cytokine
production. Together, these data suggest that NLRX1 functions
as a negative regulator of this pathway in macrophages.
To assess the physiological relevance of these findings, mice
were also subjected to an in vivo airway challenge with LPS,
where LPS was delivered to the lungs via intratracheal (i.t.) instil-
lation and themice were harvested 24 hr after challenge. Consis-
tent with the ex vivomacrophage data, LPS induced a significant
increase in IL-6 production in the Nlrx1/ mice (Figure 2G).
Histopathology assessments revealed a significant increase in
lung inflammation, which was especially concentrated around
the small airways (Figures 2H and 2I). Together, these data
suggest that NLRX1 functions as an attenuator of the TLR4
pathway in vivo in addition to its roles in attenuating MAVS-
dependent IFN-I induction.
NLRX1 Attenuates Inflammation through Interactions
with TRAF3 and TRAF6
Wenext sought to explore the underlyingmechanism associated
with the negative regulatory functions of NLRX1 during LPS stim-
ulation, which is not known to be mediated by RIG-I and MAVS.
Based on the strong effect of NLRX1 on IL-6 induction, which is
known to require TRAF and NF-kB activation, we first explored
the functional and physical interactions of NLRX1 with TRAF3
and TRAF6. In an overexpression system, NLRX1 preferentially
interacted with TRAF6 (Figure 3A, top) even though the input(E) Neutrophils andmacrophages were purified from the bonemarrow of WT andN
intensity was used to measure ROS production.
(F) Ifnb1 transcription was measured in primary MEFs isolated from Nlrx1/ mic
(G and H) IFN-b protein amounts were determined by ELISA in the supernatant
myocarditis virus (EMCV), Sendai virus (SeV), or influenza A (PR/8/34) virus.
(I and J) Ifnb gene transcription and IFN-b protein amounts were measured over a
(K and L) IL-6 concentrations were assessed by ELISA in the supernatants from
(M) Nlrx1/ MEFs were reconstituted with constructs containing full-length hu
stimulation.
(N) The association between MAVS, RIG-I, and MDA-5 were assessed by coimmu
Data shown are at time 0 and 24 hr postinfection with either SeV (RIG-I) or EMC
(O) Primary ear fibroblasts were challenged with SeV and samples were harveste
challenge in WT fibroblasts and constitutive interaction was detected in Nlrx1/
Data are presented as the mean ± standard error of the mean (SEM). *p < 0.05;amount of TRAF6 was reduced relative to TRAF3 (Figure 3A,
second gel). Interaction between overexpressed proteins can
lead to artifacts; therefore, we used LPS to activate endogenous
TRAF3, TRAF6, and IRF3 in primary bone marrow-derived
macrophages. We detected NLRX1 associations with both
TRAF3 and TRAF6 after activation with LPS (Figure 3B). In the
case of TRAF6, the interaction with NLRX1 was detected within
15 min of LPS stimulation. However, NLRX1 weakly associated
with TRAF3 under both resting conditions and throughout the
stimulation period (Figure 3B).We did not detect any interactions
between NLRX1 and IRF3 in bone marrow macrophages after
LPS exposure (Figure 3C).
We next utilized an overexpression system to assess the
functional relevance of NLRX1 on TRAF6-mediated NF-kB
activation. NLRX1 transfection dose dependently inhibited
TRAF6-mediated induction of the NF-kB expression construct
(Figures 3D and 3E). Under the resting state, the NF-kB hetero-
dimer (p50-p65) is sequestered in the cytoplasm through its
association with IkBa. Stimulation of cells results in the rapid
phosphorylation, ubiquitination, and subsequent degradation
of IkBa, which results in the subsequent phosphorylation and
activation of the p65 subunit and NF-kB activity. To evaluate
the effect of NLRX1 on NF-kB, MEFs were generated from
Nlrx1/ mice and stimulated with LPS for up to 1 hr and the
amounts of IkBa and phosphorylated p65 (pp65) were assessed.
After 30 min of LPS exposure, pp65 was markedly increased in
the WT cells, but this process was accelerated in MEFs derived
from Nlrx1/ mice. A higher amount of pp65 was detected in
naive Nlrx1/ MEFs and further increased by 10 min of LPS
stimulation (Figure 3F). Consistent with these findings, the
amounts of IkBa were reduced or not detected in Nlrx1/ cells
when compared to theWT controls. These results suggest that in
addition to serving as an attenuator of IFN-I responses, NLRX1
also inhibits LPS-induced TRAF6 activation of NF-kB. We also
evaluated pp65 activation after TNF-a stimulation. We observed
a significant increase in pp65 within 5 min of stimulation in cells
from both sets of mice. However, no significant differences in
pp65 amounts were observed between WT and Nlrx1/ in
response to TNFR activation (Figure S1K).
Nlrx1–/– Mice Showed Enhanced Viral Clearance
but Increased Lung Pathology and IL-6 Amounts
after Influenza Virus Infection
Because isolated fibroblasts from Nlrx1/mice exhibit a signifi-
cant increase in viral-induced IFN-I and IL-6 production ex vivo,lrx1/mice and were activated for 1 hr in the presence of DHR. Fluorescence
e after challenges with vesicular stomatitis virus (VSV).
s from Nlrx1/ MEFs after stimulation with simian virus 5 (SV5), encephalo-
time course SeV infection in primary ear fibroblasts isolated fromNlrx1/mice.
primary Nlrx1/ MEFs after SV5, SeV, VSV, and influenza virus infection.
man NLRX1 and assessed for Ifnb1 and Il6 gene transcription after poly(I:C)
noprecipitation in primary ear fibroblasts isolated from WT and Nlrx1/ mice.
V (MDA-5).
d over a time course. The RIG-I-MAVS association was detected 6 hr after SeV
fibroblasts.
**p < 0.005. See also Figure S1.
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Figure 2. NLRX1 Attenuates LPS-Mediated IFN-b and Cytokine Production in Mouse Macrophages
(A and B) Ifnb1 transcript and IFN-b protein were measured in bone marrow macrophages that were isolated from WT and Nlrx1/ mice after transfection with
either poly(I:C) or 30PPP-RNA.
(C) IL-6 production was measured in bone marrow macrophages isolated from WT and Nlrx1/ mice after transfection with poly(I:C).
(D–F) IFN-b, IL-6, and IL-1b protein amounts were assessed in bone marrow-derived macrophages that were challenged with LPS.
(G–I) Mice were challenged with LPS via i.t. instillation and monitored for changes in morbidity and innate immune responses.
(G) IL-6 concentrations were assessed by ELISA in BALF from WT and Nlrx1/ mice, 24 hr after LPS challenge.
(H) Semiquantitative histopathological scoring was utilized to quantify lung histopathology 24 hr after LPS challenge.
(I) Peribroncholar and perivascular cuffing localized around the small- and medium-sized airways was a characteristic feature of the Nlrx1/ histopathology.
Data are presented as the mean ± standard error of the mean (SEM). See also Figure S1.
Immunity
NLRX1 Is a Negative Regulator of Viral Immunitywe hypothesized that influenza virus infection of Nlrx1/ mice
would result in phenotypic and cytokine alterations in vivo. To
test this hypothesis, we performed an intranasal exposure of
WT and Nlrx1/ mice with mouse-adapted influenza A/PR/8/
34 (H1N1) virus and characterized disease progression. By
6 days postinfection (dpi), Nlrx1/ mice exhibited significant
morbidity as reflected by a rapid weight loss (Figure 4A).
However, this increase in morbidity was not sufficient to cause
an increase in mortality (Figure 4B). We utilized plaque assays
from lung homogenates, which were collected over a 16 day
time course, to determine the viral titer. We did not observe
any significant differences in viral load between the WT and
Nlrx1/ mice through day 6 (Figure 4C). However, by day 11858 Immunity 34, 854–865, June 24, 2011 ª2011 Elsevier Inc.the virus had been cleared from the Nlrx1/ mice and was still
present in the WT animals (Figure 4C). This suggests that the
Nlrx1/ mice are more efficient at viral clearance compared to
theWT animals. We also examined histological sections through
the main bronchiole of the left lung lobe for signs of morpholog-
ical changes or inflammation at the 6 day time point. Airway
epithelial cells showed substantial denuding and marked airway
occlusion was observed throughout the lungs of Nlrx1/ mice
(Figure 4D). Furthermore, double-blinded histological scoring
(scale of 1–3) of lung sections were conducted and confirmed
significantly increased airway epithelial injury (Figure 4E). We
also found Nlrx1 to be highly expressed in primary mouse
tracheal epithelial cell cultures (Figure 4F). Influenza virus
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Figure 3. NLRX1 Functions as an Inhibitor of
TRAF6 and NF-kB
(A) Overexpression systems were utilized to
assess NLRX1 interactions with TRAF6. HEK293T
cells were transfected with HA-NLRX1 and either
myc-TRAF-3 or myc-TRAF-6. Myc-TRAFs were
immunoprecipitated and the blot was probed with
HA-HRP antibody, myc-HRP, and GAPDH-HRP.
(B and C) NLRX1 associations with TRAF6, TRAF3
and IRF3 were determined after LPS stimulation in
primary bone marrow-derived macrophages.
(D and E) NF-kB luciferase activity was determined
in transfected 293T cells in the presence of
increasing concentrations of input NLRX1 after
stimulation with TRAF3 and TRAF6.
(F) Phosphorylation of p65 and amounts of the
inhibitor IkBa were assessed throughout a time
course of LPS stimulation in MEFs.
All studies were repeated a minimum of three
times. Data are presented as the mean ± standard
error of themean (SEM). *p < 0.05; **p < 0.005. See
also Figure S1.
Immunity
NLRX1 Is a Negative Regulator of Viral Immunityinfection typically induces airway inflammation and low levels of
airway epithelial cell injury and denuding (Buchweitz et al., 2007).
However, the excessive histopathology observed in the Nlrx1/
mice is more consistent with features typically associated with
a hyperinflammatory response and increased cell death and is
consistent with the increased production of interferons (Bala-
chandran et al., 2000; Lechner et al., 2008). These data support
the conclusion that NLRX1 is indeed functioning as an in vivo
attenuator of influenza virus-induced inflammation and that
loss of this critical regulator results in increased lung injury and
morbidity. However, a beneficial effect of this increased epithe-
lial cell denuding and interferon response may be enhanced viral
clearance in the Nlrx1/ mice.
We next sought to assess the effects of NLRX1 on cytokines
known to play roles in the host immune responses to influenza
virus. IL-1b, TNF-a, IL-12, and IL-6 facilitate a wide spectrum
of immunologic functions during respiratory virus infection. No
significant differences in serum concentrations of IL-1b, TNF-a,
and IL-12p40were detected in theWT andNlrx1/ animals (Fig-
ure 4G). However, influenza virus-induced IL-6 expression has
been linked to robust immunity to viral infection. Consistent
with the differences in morbidity and lung damage, IL-6 was
significantly elevated in the serum of Nlrx1/ mice, compared
to theWT animals (Figure 4G). In addition to serum, we also eval-
uated local cytokine concentrations in lung homogenates over
the time course infection. We observed a significant increase
in IL-6 and IFN-b amounts in the Nlrx1/ lungs (Figures 4H
and 4I; Figure S2). Together, these data are consistent with our
ex vivo observations, which show that the removal of NLRX1
results in exacerbated IL-6 and IFN-b responses after in vivo
influenza virus infection. We considered the possibility that the
increase in IL-6 could be associated with the increase in airway
epithelial cell denuding observed in the Nlrx1/mice. However,
additional pharmacological experiments with an IL-6 receptor
antagonist suggest that this pleiotropic cytokine does not
contribute to the observed lung pathology, which might be
caused by other cytokines or IFN-b (Figure S3).NLRX1 Functions In Vivo as a Negative Regulator
of the IFN-I Response to Influenza Virus Challenge
A direct assessment of IFN-I in animal tissues is difficult. How-
ever, downstream genes that are IFN-I responsive are frequently
used as a surrogate marker for induction. To further investigate
the specific cytokine milieu that is upregulated in the lungs of
Nlrx1/ mice, we performed expression profiling of a large
subset of cytokines and interferon response genes in lung
homogenates after influenza virus challenge (Figure S4A). Con-
sistent with its role as a negative regulator of IFN-I responses,
we detected a greater than 3-fold upregulation of Ifna2, Ifnb1,
Oas1a, and Stat2 gene expression in the lungs of Nlrx1/
mice compared to WT animals. We also observed a greater
than 4-fold increase in Cd70, a cytokine known to be expressed
only by activated, but not by resting, T and B lymphocytes
(Figure 5A). Only three genes, H2-M10.1, H2-M10.6, and Oas2,
were found to be greater than 2-fold upregulated in the
lungs of naive Nlrx1/ mice compared to naive WT animals
(Figures S4B and S4C). Ingenuity Pathway Analysis identified
IFN-b, STAT2, and OAS1 as downstream effectors of influenza
virus-induced RIG-I and MAVS signaling (Figure 5B). These
differences were confirmed by real-time PCR measurements
(Figure 5C).
The influenza virus encodes an NS1 protein that functions as
a brake on host RIG-I-mediated antiviral immunity (Guo et al.,
2007; Pichlmair et al., 2006). We next sought to investigate the
effects on lung cytokine production after infection of Nlrx1/
mice with the influenza A/PR/8mut39 virus, which possesses
a point mutation in the NS1 protein that attenuates the virus’s
ability to inhibit IFN-I production (Hayman et al., 2007). Our initial
in vivo studies with the influenza A/PR/8mut39 virus revealed no
significant differences in mortality or viral titer inWT andNlrx1/
mice infected with themutant virus compared to the control virus
(Figures S5A and S5B). Similar to the Nlrx1/ mice that were
challenged with the influenza A/PR/8 virus, WT mice that were
infected with the influenza A/PR/8mut39 virus demonstrated
a significant increase in lung histopathology, includingImmunity 34, 854–865, June 24, 2011 ª2011 Elsevier Inc. 859
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Figure 4. Characterization of the In Vivo Host Immune Response in Nlrx1–/– Mice after Influenza Virus A/PR/8/34 Infection
(A and B) Morbidity (weight loss) and mortality were measured for 14 days in Nlrx1/ and WT mice after in vivo intranasal administration of influenza virus
A/PR/8/34.
(C) Lungs were harvested at specific time points and homogenized to assess influenza viral titers, which were determined by standard plaque assay.
(D) Lungs were harvested 3 dpi and fixed by inflation and immersion in buffered PFA. Sections through the main bronchiole of the left lobe revealed increased
airway epithelial cell denuding (red arrows) and small airway obstruction throughout the lungs of Nlrx1/ mice.
(E) Histological scoring of H&E-stained lung sections for airway epithelial defects.
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Immunity
NLRX1 Is a Negative Regulator of Viral Immunitya significant increase in airway epithelial cell denuding and small
airway occlusion (Figure S5C). Consistent with our hypothesis
that the influenza virus NS1 protein and host NLRX1 protein
target similar components of the RIG-I pathway, in vivo, we
observed that infection of WT mice with the influenza A/PR/
8mut39 virus resulted in significantly increased cytokine mRNA
expression (Il6, Ifnb1, Stat2, and Oas1a) compared to the WT
control virus (Figure 5D). Interestingly, we observed a significant
increase in lung expression of Il6, Ifnb1, Stat2, and Oas1a when
Nlrx1/ mice were exposed to A/PR/8mut39, which extended
beyond what was observed in WT animals (Figure 5D). There-
fore, as illustrated in the model shown in Figure S5D, releasing
both the viral (NS1) and host (NLRX1) negative regulators of
the RIG-I and MAVS pathway led to even further exacerbation
of components of the host innate immune response.
NLRX1 Attenuates the IFN-b-STAT2-OAS1 Axis
in Response to the 2009 Pandemic Influenza
A/California/08/09 Virus
To evaluate the relevance of these findings in the context of
human diseases, we evaluated the role of NLRX1 in the pan-
demic influenza A/California/08/09 (H1N1) virus. The pandemic
virus was not mouse adapted at the time of our studies and
was restricted to use under BSL3 conditions. Therefore, we did
not use this virus in vivo. Instead, we chose a stable shRNA
knockdown approach in human cells, which achieved a near-
complete knockdown of NLRX1 mRNA and protein in 293T cells
(Figures 6A and 6B). Infection with pandemic influenza A virus at
an MOI of 0.1 was verified by immunoblot for the influenza virus
NS1 protein (Figure 6C). Congruent with our in vivo findings, we
observed a significant increase in IL6, IFNB1, STAT2, and OAS1
mRNA in cells bearing shNLRX1 after infections with the
pandemic influenza virus (Figure 6D). These data suggest that,
similar to the other influenza viruses used in this study, NLRX1
also functions as an attenuator of the IFN-b-IL6 axis in response
to influenza A/California/08/09 virus in human cells.
DISCUSSION
The observations based on the study of Nlrx1/ mice solidify
a role for NLRX1 as an in vivo checkpoint of IFN-I and IL-6
responses and additionally identifies a linkage between
NLRX1, TRAF6, and NF-kB signaling. We have extended
these findings to the influenza virus and identified an NLR that
functions as an attenuator of host immune responses to this
important human pathogen. Prior to this work, it was unclear
whether inhibitors of RIG-I-MAVS reduced antiviral immunity or
attenuated hyperinflammatory responses in vivo. This report
supports the hypothesis that NLRX1 functions as an in vivo
cellular brake on both RIG-I-MAVS-dependent and MAVS-inde-(F) Basal amounts of Nlrx1 transcription was measured in primary bone marrow-d
naive WT mice.
(G) Serum was harvested from Nlrx1/ and WT mice 3 dpi with influenza A/PR
measured.
(H and I) Whole lungs were harvested from WT and Nlrx1/ mice at specific time
were determined in cell-free supernatants by ELISA.
All studies were repeated aminimumof three timeswith five to sevenmice per gro
the mean (SEM). *p < 0.05; **p < 0.005. See also Figures S2 and S3.pendent signaling pathways; therefore, NLRX1 probably func-
tions to prevent unwarranted or overwhelming host inflammatory
responses to a variety of viruses. The finding that NLRX1 func-
tions as a negative regulator of RIG-I-MAVS-dependent sig-
naling in response to viruses and dsRNA is consistent with the
findings that Nlrx1/ mice exhibited significant morbidity, lung
injury, and inflammation after influenza virus challenge.
Several recent studies have described a role for NLR proteins
in mediating innate immune responses to virus. Recent studies
have shown that components of the NLRP3 inflammasome
(NLRP3, Pycard, and Caspase-1) function, in vivo, to mediate
the innate immune response to influenza virus (Allen et al.,
2009; Thomas et al., 2009). These studies demonstrate that
NLRP3mediates the posttranslational modification of proinflam-
matory cytokines (IL-1b and IL-18) in response to influenza virus
infection. In addition to NLRP3, recent evidence has also sug-
gested that NOD2 (a member of the NLR family) also senses viral
RNA and appears to interact with MAVS (Sabbah et al., 2009).
The NOD2-MAVS interaction is dependent on the NBD and
LRR domains of NOD2, which is similar to the mechanism of
interaction that has been proposed for NLRX1-MAVS (Moore
et al., 2008). Thus, it is interesting that the binding of NOD2 to
MAVS appears to induce IFN-I production through IRF3 activa-
tion (Sabbah et al., 2009), whereas the binding of NLRX1 to
MAVS attenuates this pathway (Moore et al., 2008).
One of the mechanisms by which NLRX1 attenuates MAVS
activation is probably through direct competition with the
RIG-I-MAVS interaction, shown previously in vitro (Moore
et al., 2008). Our findings with Nlrx1/ cells shows that MAVS
and RIG-I constitutively interact with one another; however,
this interaction is not sufficient to cause IFN-I induction. Instead,
viral infection is needed to induce IFN-I, suggesting that in addi-
tion to the MAVS-RIG-I interaction, an additional viral-induced
step is also required. The production of IFN-I after virus infection
is dependent upon the RLH signaling pathway, which is tightly
controlled through a complex series of both positive and nega-
tive regulators. One purpose of this regulation scheme is to
protect the host from an overzealous and potentially detrimental
innate immune response. A variety of molecules have recently
been described as negative regulators of virus-initiated RLH
signaling and have been proposed to function through similar
mechanisms as those described here for NLRX1 (Moore et al.,
2008). For instance, LGP2 is a RLH that is induced after viral
infection and is functionally similar to RIG-I. However, LGP2
can function as a negative regulator by inhibiting RIG-I multime-
rization and competing withMAVS for binding with IKK3 (Komuro
and Horvath, 2006). Similar to the data shown here for NLRX1,
LGP2 appears to have differential effects on RIG-I and MDA5
signaling. LGP2 has been shown to inhibit RIG-I signaling and
augment MDA5 signaling in response to VSV and EMCV,erived macrophages (BMDM) and mouse tracheal epithelial cells (MTECs) from
/8/34 virus, and the concentrations of IL-1b, TNF-a, IL-12p40, and IL-6 were
points after i.n. infection with influenza A/PR/8/34 virus. IL-6 and IFN-b levels
up for each individual study. Data are presented as themean ± standard error of
Immunity 34, 854–865, June 24, 2011 ª2011 Elsevier Inc. 861
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Figure 5. NLRX1 Functions In Vivo as a Negative Regulator of the IFN-I Response to Influenza Virus Challenge
(A) Gene expression was profiled for genes associated with IFN-I and viral innate immunity. Whole lungs were harvested from WT and Nlrx1/ mice, 20 hr
postintratracheal (i.t.) inoculation with the influenza A/PR/8/34 virus. RNA was extracted and pooled in equal quantities for similarly treated mice from each
genotype. Genes that demonstrated at least 2-fold changes in transcription between WT and Nlrx1/ mice were considered significant.
(B) The expression profile data were analyzed with Ingenuity Pathways Analysis software, which revealed several genes in the RIG-I/MAVS pathway that were
significantly upregulated in the lungs of Nlrx1/ mice.
(C) Real-time PCR was used to confirm increased Ifnb1, Stat2, and Oas1a gene expression in individual samples (unpooled and distinct from the samples used
in the array).
(D) NLRX1 and the viral NS1 protein have nonoverlapping targets. WT and Nlrx1/ mice were challenged with the influenza A/PR/8mut39 virus, which carries
a mutant NS1 protein that attenuates the virus’s ability to inhibit the IFN-I response. Il6, Ifnb1, Stat2, andOas1a gene expression was assessed by real-time PCR.
Expression profiling was repeated twice with samples pooled from three individual mice. All other studies were repeated three times with three to seven mice per
group for each individual study. Data are presented as the mean ± standard error of the mean (SEM). *p < 0.05; **p < 0.005. See also Figures S4 and S5.
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NLRX1 Is a Negative Regulator of Viral Immunityrespectively (Venkataraman et al., 2007). The Atg5-Atg12 conju-
gate is also a negative regulator of RLH signaling and has been
shown to function through a mechanism that is similar to the
one proposed for NLRX1. Atg5-Atg12 interferes with the
CARD-CARD interactions between MAVS and RIG-I to inhibit
IFN-I signaling (Jounai et al., 2007). Similar to NLRX1, in the
absence of Atg5, MEFs stimulated with VSV and poly(I:C) were
found to have significantly increased amounts of IFN-I and IL-6
(Jounai et al., 2007).
A diverse range of molecules has been identified as negative
regulators of inflammation. However, the concept that a sub-
group of NLRs functions to attenuate inflammation is a relatively862 Immunity 34, 854–865, June 24, 2011 ª2011 Elsevier Inc.new finding and has not been thoroughly analyzed in vivo with
gene-deletion mice. One of the best-characterized NLRs associ-
ated with a negative regulatory role is NLRP12. In vitro, NLRP12
has been shown to suppress inflammation by inhibiting compo-
nents of the NF-kB pathway (Lich et al., 2007). Specifically,
NLRP12 has been shown to associate with NF-kB-inducing
kinase (NIK), which in turn facilitates proteasome-mediated
degradation of this kinase and inhibition of noncanonical
NF-kB signaling (Lich et al., 2007). In addition to inhibiting nonca-
nonical NF-kB signaling, which is typically associated with the
activation of TNF family receptors, NLRP12 has also been shown
to negatively regulate TLR signaling pathways by associating
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Figure 6. NLRX1 Attenuates IL-6 and the IFN-b-STAT2-OAS1 Axis in Human Cells in Response to the 2009 Pandemic Influenza A/California/
08/09 Virus
(A and B) NLRX1 was knocked down by shRNA in 293T cells as shown by real-time PCR and immunoblot of three different shRNAs targeting NLRX1 (sh#1
to sh#3).
(C) Immunoblot for the influenza virus NS1 protein was used to confirm that cells were infected with the 2009 pandemic influenza A/California/08/09 virus at
MOI = 0.1.
(D) IL6, IFNB1, STAT2, and OAS1A gene expression were assessed in 293T cells subsequent to the targeted knockdown of NLRX1 after infection with the 2009
pandemic influenza A/California/08/09 virus (MOI = 0.1).
Experiments were repeated twice in all three NLRX1 knockdown cell lines and scrambled control cell lines. Data are presented as themean ± standard error of the
mean (SEM). *p < 0.05.
Immunity
NLRX1 Is a Negative Regulator of Viral Immunitywith activated forms of IRAK-1 (Williams et al., 2005). The asso-
ciation with IRAK-1 reduces the presence of hyperphosphory-
lated forms of IRAK-1. This results in the attenuated production
of proinflammatory cytokines, including IL-6, after LPS stimula-
tion (Williams et al., 2005). NLRC5 (a member of the NLR family)
has also been shown to be a negative regulator of NF-kB, AP-1,
and IRF3 activation in response to LPS, poly(I:C), and VSV stim-
ulation in overexpression and shRNAmodels (Benko et al., 2010;
Cui et al., 2010). NLRC5 has been proposed to attenuate NF-kB
signaling by interacting with IKKa and IKKb to block phosphory-
lation and to inhibit RLH signaling by interacting with RIG-I and
MDA5 (Cui et al., 2010). However, it should be noted that some
of the negative regulatory functions associated with NLRC5
have not been observed by others (Kuenzel et al., 2010; Neerincx
et al., 2010).
In addition to intersecting with the RIG-I-MAVS pathway,
NLRX1 also attenuates NF-kB activation through its interaction
with components of the TRAF6 pathway. TRAF6 is known to
regulate a diverse range of innate immune signals and cytokines,
including NF-kB and IL-6. Indeed, we demonstrate increased
NF-kB signaling inNlrx1/ cells after LPS stimulation. This iden-
tifies TRAF6 as an interacting partner for NLRX1. The interaction
of NLRX1 with TRAF6 was also reported in Xia et al. (2011) in this
issue of Immunity. Together, our data are in contrast with an
earlier report that showed that overexpressed NLRX1 synergized
ROS-mediated NF-kB activation (Tattoli et al., 2008). The data
generated from our Nlrx1/ mice shows that NLRX1 regulation
of NF-kB occurs through a MAVS-independent pathway and isinhibitory, which is a finding that is also supported by Xia et al.
(2011). These findings suggest that NLRX1 attenuates IFN-I
and NF-kB, either partially or wholly, through separate pathways
in a cell type- and pathogen-specific manner.
From a therapeutic standpoint, it has been proposed that
targeted knockdown of negative regulators of MAVS could
enhance antiviral immune responses. This report highlights that
removal of just one of the many reported brakes of RIG-I-
MAVS signaling can indeed result in elevated responses to influ-
enza A virus. However, this comes at a price of increased
systemic exposure to proinflammatory cytokines, such as IL-6.
Further elucidation of the role of NLRX1 and other molecular
brakes on antiviral signaling and the likely bifurcation of down-
stream transcriptional activation may allow for safe and targeted
approaches to increasing host responses to viral infection.
Considering the attenuating effects of NLRX1 on pulmonary
inflammation shown here, this protein is likely to have a broad
and complex role in the control of inflammatory diseases beyond
viral infection.
EXPERIMENTAL PROCEDURES
Mouse Generation
The Nlrx1/ mice were generated as illustrated in Figure 1A. Exons 4 and 5
(NBD domain) ofNlrx1were replacedwith aNeo cassette. The targeting vector
was confirmed by restriction analysis and by sequencing. The linearized
targeting vector was electroporated into IC1 C57BL/6 embryonic stem (ES)
cells (InGenious targeting Labs, New York). Homologous recombinants were
verified and injected into BALB/c blastocysts. The resulting chimeras wereImmunity 34, 854–865, June 24, 2011 ª2011 Elsevier Inc. 863
Immunity
NLRX1 Is a Negative Regulator of Viral Immunitymated with female C57BL/6J mice and the resulting heterozygotes were
crossed to produce homozygous Nlrx1/ mice. All mouse studies were con-
ducted in accordance with the NIH Guide for the Care and Use of Laboratory
Animals and the IACUC guidelines of UNC Chapel Hill.
Ex Vivo Primary Cell Challenges
Primary fibroblasts (MEFs and ear fibroblasts), bone marrow-derived macro-
phages, and pDCs were isolated and cultured by standard procedures. To
assess PAMP stimulation, cells were challenged with either poly(I:C) or
30PPP-RNA (transfected with Lipofectamine 2000 [Sigma]), LPS (1 mg/ml;
Escherichia coli, sterile serotype 0111:B4 [Sigma]), TNF-a, or Pam3CSK4.
Unless otherwise stated, all cells were treated with 30 MOI of each virus or 1
MOI of each bacterium, except Legionella, which was used at 0.01 MOI. For
assessments of ROS, neutrophils and macrophages were purified from bone
marrow via a discontinuous Percoll gradient. The leukocytes were resus-
pended and incubated with dihydrorhodamine-123 (DHR) (ANAspec) and
the respective stimuli for 1 hr. Cells were then washed and analyzed for
fluorescence intensities with a CyAn ADP high-resolution cytometer (DAKO).
Alternatively, blood was collected and incubated with DHR and the respective
stimuli, after red cell lysis, and fluorescence intensities were acquired with flow
cytometry. In this case, high side scatter and high forward scatter cell popula-
tions were selected for analysis.
In Vivo Influenza A Virus Infection
Animals were anesthetized and challenged by either intratracheal (i.t.) admin-
istration of LPS (1mg/ml) or intranasal (i.n.) administration of 63 104 PFU/ml of
influenza virus A/PR/8/34 or A/PR/8/34mut39. Mice were observed and weight
was assessed daily for up to 14 dpi. Mice were euthanized either 3 or 7 dpi, and
serum was collected after cardiac puncture. Total cytokine amounts were
determined by ELISA. For histopathologic examination, lungs were fixed by
inflation and immersion in buffered formalin and subjected to H&E staining.
Lung sections were scored based on assessments of mononuclear and poly-
morphonuclear cell infiltration, perivascular and peribronchiolar cuffing, and
estimates of the percent of lung involved with the disease, while blinded to
genotype and treatment. Epithelial cell defects were determined based on
the severity and extent of damage to the epithelial cell layer.
Expression Profiling
Mice were challenged by intrachael (i.t.) administration of 6 3 104 PFU/ml of
influenza virus A/PR/8/34 and sacrificed 16–20 hr postinfection. Total RNA
was isolated from whole lungs. RNA from three different animals was pooled
together prior to the cDNA reaction. Pooled samples were analyzed with
RT2 Profiler PCR Arrays (SABiosystems) according to the manufacturer’s
protocols or by Taqman rtPCR analysis (ABI). Array results were confirmed
on total RNA from individual mice that were challenged independently of those
used for array profiling. The array data were analyzed with Ingenuity Pathways
Analysis software (Ingenuity Systems).
Lentivirus-Based Delivery of NLRX1-Targeting shRNA
The NLRX1-targeting shRNA sequences and scrambled control sequences
were cloned into the lentiviral vector FG12 according to standard molecular
cloning protocols and NLRX1 expression was reduced in HEK293T cells.
The shRNA hairpin sequences used were: sh-scrambled, 50-GCACATCGCT
TCTCGGGATTCTCTTGAAATCCCGAGAAGCGATGTGC-30; and sh-NLRX1,
50-GCACATCTTCCGTCGGGATTCTCTTGAAATCCCGACGGAAGATGTGC-30.
The altered sequences in the control scrambled construct are underlined.
Influenza Virus A/Californina/08/09 Infection of NLRX1 Knockdown
Cell Lines
NLRX1 knockdown cell lines (HEK293T) were challenged with influenza
A/California/08/09 (H1N1) virus for 2 hr at 37C (MOI = 0.1). After incubation,
supernatant was replaced with fresh media and cells were incubated at
37C. Cell-free supernatants were harvested at select time points for viral titer.
Cells were harvested and the RNA was extracted for RT-PCR analysis.
Luciferase Reporter Assays
Detailed protocols for cell culture and luciferase assays have been previously
published (Moore et al., 2008). In brief, 293T cells were plated at 125,000/well864 Immunity 34, 854–865, June 24, 2011 ª2011 Elsevier Inc.in a 24-well plate. Cells were transfected with Fugene6 (Roche) with 150 ng
kB-luciferase reporter plasmid; 250 ng myc-TRAF-3 or -6; 0, 100, or 250 ng
HA-NLRX1; and 250, 150, or 0 ng of carrier pcDNA3.1 to bring the total to
900 ng of DNA. To assess TNF-a stimulation, cells were treated with 0, 5,
10, or 50 ng of TNF-a. After 24 hr, the cells were washed with PBS then lysed
with 13 Reporter Lysis Buffer (Promega). ATP (gly-gly, KHPO4, MgSO4,
EGTA, ATP, DTT) and luciferin (gly-gly, D-luciferin, DTT) buffers were added
to the lysate and relative light units were measured on a luminometer.
Coimmunoprecipitation
Detailed protocols for cell culture, coimmunoprecipitation, and antibodies
used have been previously published (Moore et al., 2008). In brief, 2 3 106
HEK293T cells were plated in a 10 cm2 culture dish. Cells were transfected
with Fugen6 (Roche) with 3 mg HA-NLRX1 and 2 mg of myc-TRAF-3 or myc-
TRAF-6. After 24 hr, cells were washed with PBS, lysed in 1% Triton X-100.
Lysates were centrifuged at 16,000 rpm to remove nuclei. Myc-TRAFs were
immunoprecipitated with myc-agarose beads overnight. The beads were
washed three times and samples were run on NUPAGE Bis-Tris 4%–12%
gels. Blots were probed with HA-HRP antibody (Santa Cruz), myc-HRP (Santa
Cruz), and GAPDH-HRP (Santa Cruz). Immunoblots for transfected NLRX1
were performed on immunoprecipitants of endogenous TRAF6. For endoge-
nous immunoblots, cell extracts were precleared with protein A/G agarose
beads (Thermo Scientific) for 60 min at 4C and then incubated with 2 mg of
rabbit IgG, TRAF3, or TRAF6 primary antibodies overnight at 4C. Protein
A/G ultralink resin (Thermo Scientific) was then added to the samples and
incubated for 2 hr at 4C. Immunoprecipitated proteins were blotted for
endogenous NLRX1 as described (Moore et al., 2008).
Statistical Analysis
Unless otherwise stated, all experiments were repeated a minimum of three
times. All of the data are presented as the mean ± the standard error of the
mean (SEM). To assess complex data sets from both individual experiments
and composite data, we utilized an analysis of variance (ANOVA) followed
by either the Tukey-Kramer HSD or Newman-Keuls Post Test for multiple
comparisons. To assess single data points, we conducted a Student’s two-
tailed t test to determine significance. To assess survival, we generated
survival curves with the product limit method of Kaplan and Meier. We utilized
the log rank test to compare survival curves. A p value < 0.05 was considered
statistically significant for all data.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and can be found with this
article online at doi:10.1016/j.immuni.2011.03.026.
ACKNOWLEDGMENTS
The authors would like to thank W.S. Barclay (Imperial College London) for
providing the influenza A/PR/8/34mut39 virus. We would also like to thank
J.M. Katz and N.J. Cox of the Influenza Division for their support. This work
is supported by U54-AI057157 (SERCEB), U19-AI067798, U19-AI077437
(J.P.Y.T.), F32-AI-082895-01, T32-AR007416, and T32-CA009156 (I.C.A.).
Received: November 12, 2010
Revised: March 4, 2011
Accepted: March 26, 2011
Published online: June 23, 2011
REFERENCES
Abdul-Sater, A.A., Saı¨d-Sadier, N., Lam, V.M., Singh, B., Pettengill, M.A.,
Soares, F., Tattoli, I., Lipinski, S., Girardin, S.E., Rosenstiel, P., and Ojcius,
D.M. (2010). Enhancement of reactive oxygen species production and chla-
mydial infection by the mitochondrial Nod-like family member NLRX1.
J. Biol. Chem. 285, 41637–41645.
Allen, I.C., Scull, M.A., Moore, C.B., Holl, E.K., McElvania-TeKippe, E.,
Taxman, D.J., Guthrie, E.H., Pickles, R.J., and Ting, J.P. (2009). The NLRP3
Immunity
NLRX1 Is a Negative Regulator of Viral Immunityinflammasome mediates in vivo innate immunity to influenza A virus through
recognition of viral RNA. Immunity 30, 556–565.
Balachandran, S., Roberts, P.C., Kipperman, T., Bhalla, K.N., Compans, R.W.,
Archer, D.R., and Barber, G.N. (2000). Alpha/beta interferons potentiate virus-
induced apoptosis through activation of the FADD/Caspase-8 death signaling
pathway. J. Virol. 74, 1513–1523.
Benko, S., Magalhaes, J.G., Philpott, D.J., and Girardin, S.E. (2010). NLRC5
limits the activation of inflammatory pathways. J. Immunol. 185, 1681–1691.
Buchweitz, J.P., Harkema, J.R., and Kaminski, N.E. (2007). Time-dependent
airway epithelial and inflammatory cell responses induced by influenza virus
A/PR/8/34 in C57BL/6 mice. Toxicol. Pathol. 35, 424–435.
Cui, J., Zhu, L., Xia, X., Wang, H.Y., Legras, X., Hong, J., Ji, J., Shen, P., Zheng,
S., Chen, Z.J., and Wang, R.F. (2010). NLRC5 negatively regulates the
NF-kappaB and type I interferon signaling pathways. Cell 141, 483–496.
Guo, Z., Chen, L.M., Zeng, H., Gomez, J.A., Plowden, J., Fujita, T., Katz, J.M.,
Donis, R.O., and Sambhara, S. (2007). NS1 protein of influenza A virus inhibits
the function of intracytoplasmic pathogen sensor, RIG-I. Am. J. Respir. Cell
Mol. Biol. 36, 263–269.
Hayman, A., Comely, S., Lackenby, A., Hartgroves, L.C., Goodbourn, S.,
McCauley, J.W., and Barclay, W.S. (2007). NS1 proteins of avian influenza A
viruses can act as antagonists of the human alpha/beta interferon response.
J. Virol. 81, 2318–2327.
Jia, Y., Song, T., Wei, C., Ni, C., Zheng, Z., Xu, Q., Ma, H., Li, L., Zhang, Y., He,
X., et al. (2009). Negative regulation of MAVS-mediated innate immune
response by PSMA7. J. Immunol. 183, 4241–4248.
Jounai, N., Takeshita, F., Kobiyama, K., Sawano, A., Miyawaki, A., Xin, K.Q.,
Ishii, K.J., Kawai, T., Akira, S., Suzuki, K., and Okuda, K. (2007). The Atg5
Atg12 conjugate associates with innate antiviral immune responses. Proc.
Natl. Acad. Sci. USA 104, 14050–14055.
Kato, H., Sato, S., Yoneyama, M., Yamamoto, M., Uematsu, S., Matsui, K.,
Tsujimura, T., Takeda, K., Fujita, T., Takeuchi, O., and Akira, S. (2005). Cell
type-specific involvement of RIG-I in antiviral response. Immunity 23, 19–28.
Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K.,
Uematsu, S., Jung, A., Kawai, T., Ishii, K.J., et al. (2006). Differential roles of
MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441,
101–105.
Kawai, T., Takahashi, K., Sato, S., Coban, C., Kumar, H., Kato, H., Ishii, K.J.,
Takeuchi, O., and Akira, S. (2005). IPS-1, an adaptor triggering RIG-I- and
Mda5-mediated type I interferon induction. Nat. Immunol. 6, 981–988.
Komuro, A., and Horvath, C.M. (2006). RNA- and virus-independent inhibition
of antiviral signaling by RNA helicase LGP2. J. Virol. 80, 12332–12342.
Kuenzel, S., Till, A., Winkler, M., Ha¨sler, R., Lipinski, S., Jung, S., Gro¨tzinger, J.,
Fickenscher, H., Schreiber, S., and Rosenstiel, P. (2010). The nucleotide-
binding oligomerization domain-like receptor NLRC5 is involved in IFN-depen-
dent antiviral immune responses. J. Immunol. 184, 1990–2000.
Le Goffic, R., Pothlichet, J., Vitour, D., Fujita, T., Meurs, E., Chignard, M., and
Si-Tahar, M. (2007). Cutting edge: Influenza A virus activates TLR3-dependent
inflammatory and RIG-I-dependent antiviral responses in human lung epithe-
lial cells. J. Immunol. 178, 3368–3372.
Lechner, J., Malloth, N., Seppi, T., Beer, B., Jennings, P., and Pfaller, W.
(2008). IFN-alpha induces barrier destabilization and apoptosis in renal
proximal tubular epithelium. Am. J. Physiol. Cell Physiol. 294, C153–C160.
Lich, J.D., Williams, K.L., Moore, C.B., Arthur, J.C., Davis, B.K., Taxman, D.J.,
and Ting, J.P. (2007). Monarch-1 suppresses non-canonical NF-kappaBactivation and p52-dependent chemokine expression in monocytes.
J. Immunol. 178, 1256–1260.
Moore, C.B., Bergstralh, D.T., Duncan, J.A., Lei, Y., Morrison, T.E.,
Zimmermann, A.G., Accavitti-Loper, M.A., Madden, V.J., Sun, L., Ye, Z.,
et al. (2008). NLRX1 is a regulator of mitochondrial antiviral immunity. Nature
451, 573–577.
Neerincx, A., Lautz, K., Menning, M., Kremmer, E., Zigrino, P., Ho¨sel, M.,
Bu¨ning, H., Schwarzenbacher, R., and Kufer, T.A. (2010). A role for the human
nucleotide-binding domain, leucine-rich repeat-containing family member
NLRC5 in antiviral responses. J. Biol. Chem. 285, 26223–26232.
Pichlmair, A., Schulz, O., Tan, C.P., Na¨slund, T.I., Liljestro¨m, P., Weber, F., and
Reis e Sousa, C. (2006). RIG-I-mediated antiviral responses to single-stranded
RNA bearing 50-phosphates. Science 314, 997–1001.
Rehwinkel, J., Tan, C.P., Goubau, D., Schulz, O., Pichlmair, A., Bier, K., Robb,
N., Vreede, F., Barclay, W., Fodor, E., and Reis e Sousa, C. (2010). RIG-I
detects viral genomic RNA during negative-strand RNA virus infection. Cell
140, 397–408.
Sabbah, A., Chang, T.H., Harnack, R., Frohlich, V., Tominaga, K., Dube, P.H.,
Xiang, Y., and Bose, S. (2009). Activation of innate immune antiviral responses
by Nod2. Nat. Immunol. 10, 1073–1080.
Seth, R.B., Sun, L., Ea, C.K., and Chen, Z.J. (2005). Identification and charac-
terization of MAVS, a mitochondrial antiviral signaling protein that activates
NF-kappaB and IRF 3. Cell 122, 669–682.
Sun, Q., Sun, L., Liu, H.H., Chen, X., Seth, R.B., Forman, J., and Chen, Z.J.
(2006). The specific and essential role of MAVS in antiviral innate immune
responses. Immunity 24, 633–642.
Tattoli, I., Carneiro, L.A., Je´hanno, M., Magalhaes, J.G., Shu, Y., Philpott, D.J.,
Arnoult, D., and Girardin, S.E. (2008). NLRX1 is a mitochondrial NOD-like
receptor that amplifies NF-kappaB and JNK pathways by inducing reactive
oxygen species production. EMBO Rep. 9, 293–300.
Thomas, P.G., Dash, P., Aldridge, J.R., Jr., Ellebedy, A.H., Reynolds, C., Funk,
A.J., Martin, W.J., Lamkanfi, M., Webby, R.J., Boyd, K.L., et al. (2009). The
intracellular sensor NLRP3 mediates key innate and healing responses to
influenza A virus via the regulation of caspase-1. Immunity 30, 566–575.
Venkataraman, T., Valdes, M., Elsby, R., Kakuta, S., Caceres, G., Saijo, S.,
Iwakura, Y., and Barber, G.N. (2007). Loss of DExD/H box RNA helicase
LGP2 manifests disparate antiviral responses. J. Immunol. 178, 6444–6455.
Williams, K.L., Lich, J.D., Duncan, J.A., Reed, W., Rallabhandi, P., Moore, C.,
Kurtz, S., Coffield, V.M., Accavitti-Loper, M.A., Su, L., et al. (2005). The
CATERPILLER protein monarch-1 is an antagonist of toll-like receptor-, tumor
necrosis factor alpha-, and Mycobacterium tuberculosis-induced pro-inflam-
matory signals. J. Biol. Chem. 280, 39914–39924.
Xia, X., Cui, J.,Wang, H.Y., Zhu, L.,Matsueda, S.,Wang, Q., Yang, X., Hong, J.,
Songyang, Z., Chen, Z.J., andWang, R.-F. (2011). NLRX1 negatively regulates
TLR-induced NF-kB signaling by targeting TRAF6 and IKK. Immunity 34, this
issue, 843–853.
Xu, L., Xiao, N., Liu, F., Ren, H., and Gu, J. (2009). Inhibition of RIG-I and
MDA5-dependent antiviral response by gC1qR at mitochondria. Proc. Natl.
Acad. Sci. USA 106, 1530–1535.
Yasukawa, K., Oshiumi, H., Takeda, M., Ishihara, N., Yanagi, Y., Seya, T.,
Kawabata, S., and Koshiba, T. (2009). Mitofusin 2 inhibits mitochondrial
antiviral signaling. Sci. Signal. 2, ra47.
You, F., Sun, H., Zhou, X., Sun, W., Liang, S., Zhai, Z., and Jiang, Z. (2009).
PCBP2 mediates degradation of the adaptor MAVS via the HECT ubiquitin
ligase AIP4. Nat. Immunol. 10, 1300–1308.Immunity 34, 854–865, June 24, 2011 ª2011 Elsevier Inc. 865
